Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Health Care Organization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    279 result(s) found for: Health Care Organization. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-001028-16 Sponsor Protocol Number: EARLY-DEX Start Date*: 2021-05-21
    Sponsor Name:Fundación para la Investigación e Innovación Biomédica (FIIB) del Hospital Universitario Infanta Leonor y Hospital Unive
    Full Title: DEXamethasone EARLY administration in hospitalized patients with Covid-19 pneumonia and high risk of developing acute respiratory distress syndrome
    Medical condition: Hospitalized patients with Covid-19 pneumonia who do not require oxygen therapy on admission associated with at least two of the three following factors related with severe Covid-19: lactate dehydr...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002485-24 Sponsor Protocol Number: CHUBX2014/09 Start Date*: 2015-08-11
    Sponsor Name:CHU de Bordeaux
    Full Title: Effectiveness of oral prednisolone versus partial endodontic treatment on pain reduction in emergency care of acute irreversible pulpitis of mandibular molars: study protocol for a non inferiority ...
    Medical condition: Pulpitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002694-11 Sponsor Protocol Number: D5160C00007 Start Date*: 2014-12-17
    Sponsor Name:AstraZeneca AB
    Full Title: A phase III, double-blind, randomised study to assess the efficacy and safety of AZD9291 versus a standard of care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as first-line treatment...
    Medical condition: Locally advanced or metastatic non-small cell lung cancer, not amenable to curative surgery or radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (GB - no longer in EU/EEA) IT (Completed) DE (Completed) ES (Completed) BE (Completed) SE (Completed) CZ (Completed) FR (Completed) PL (Completed) BG (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002340-14 Sponsor Protocol Number: REMAP-CAP Start Date*: 2015-09-16
    Sponsor Name:University Medical Center Utrecht
    Full Title: Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19)
    Medical condition: Severe Community Acquired Pneumonia COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10010120 Community acquired pneumonia LLT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) IE (Trial now transitioned) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Ongoing) BE (Trial now transitioned) DE (Ongoing) HR (Ongoing) ES (Temporarily Halted) FR (Trial now transitioned) FI (Ongoing) IT (Ongoing) CZ (Trial now transitioned) SI (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001376-28 Sponsor Protocol Number: NL57885.091.16 Start Date*: 2017-04-20
    Sponsor Name:Radboud University Medical Center
    Full Title: Multi-center, randomized non-inferiority trial of early treatment versus expectative management of patent ductus arteriosus in preterm infants.
    Medical condition: Patent ductus arteriosus in the preterm infant
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Completed) LU (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-003589-10 Sponsor Protocol Number: D419LC00001 Start Date*: 2015-12-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic S...
    Medical condition: Adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who have not received prior systemic chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) GR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) PL (Completed) AT (Completed) RO (Completed) FR (Completed) PT (Completed) BG (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001366-11 Sponsor Protocol Number: Solidarity Start Date*: 2020-03-27
    Sponsor Name:FIB-HCSC [...]
    1. FIB-HCSC
    2. WHO (World Health Organization)
    Full Title: An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) LT (Ongoing) IE (Completed) IT (Ongoing) PT (Temporarily Halted) SK (Ongoing) RO (Ongoing) LV (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2012-001828-35 Sponsor Protocol Number: CA209-037 Start Date*: 2013-02-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized Open-Label Phase III Trial of BMS-936558 versus Investigator’s Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy Pharmacogenetic...
    Medical condition: Unresectable or metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) AT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-002557-56 Sponsor Protocol Number: ACT11705 Start Date*: 2011-11-24
    Sponsor Name:sanofi-aventis
    Full Title: A randomized, double-blind, parallel-group, placebo-controlled study to assess the clinical benefit of SSR411298 as adjunctive treatment for persistent cancer pain
    Medical condition: cancer pain
    Disease: Version SOC Term Classification Code Term Level
    14.1 10018065 - General disorders and administration site conditions 10069398 Breakthrough cancer pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004571-41 Sponsor Protocol Number: RBMinCovid19 Start Date*: 2021-02-23
    Sponsor Name:Cyxone AB
    Full Title: A Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety and Efficacy of Rabeximod Compared to Standard of Care in Patients With Moderate Coronavirus Disease (COVID-19)
    Medical condition: Coronavirus Disease (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Prematurely Ended) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000662-65 Sponsor Protocol Number: D5164C00001 Start Date*: 2015-08-12
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, double-blind, randomized, placebo-controlled multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation...
    Medical condition: Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following co...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029517 Non-small cell lung cancer stage I PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) IT (Ongoing) DE (Ongoing) HU (Ongoing) NL (Ongoing) ES (Ongoing) PL (Completed) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001811-94 Sponsor Protocol Number: M18-868 Start Date*: 2022-01-28
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Adva...
    Medical condition: C-Met overexpressing EGFR wildtype, non-squamous non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) CZ (Trial now transitioned) SE (Trial now transitioned) HU (Ongoing) RO (Ongoing) AT (Trial now transitioned) IT (Ongoing) NL (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001061-16 Sponsor Protocol Number: D5160C00048 Start Date*: 2018-09-04
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of Osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-posit...
    Medical condition: Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-000734-21 Sponsor Protocol Number: FL05-1 Start Date*: 2005-09-13
    Sponsor Name:Groupe d'Etude des Lymphomes de l'Adulte (GELA)
    Full Title: A Phase 2 Study of VELCADE™ in Subjects with Relapsed or Refractory follicular B-cell Lymphoma
    Medical condition: Follicular Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001644-25 Sponsor Protocol Number: ACE-ID-201/D822FC00001 Start Date*: 2020-05-06
    Sponsor Name:Acerta Pharma B.V.
    Full Title: A Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19
    Medical condition: Subjects with life-threatening COVID-19 symptoms
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001111-36 Sponsor Protocol Number: CAN04CLIN001 Start Date*: 2018-01-25
    Sponsor Name:Cantargia AB
    Full Title: An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors
    Medical condition: Solid malignant tumors, in the following two indications; Non-Small Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC),
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NO (Completed) DK (Completed) NL (Completed) DE (Completed) AT (Completed) EE (Completed) ES (Ongoing) LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002277-11 Sponsor Protocol Number: 20120123 Start Date*: 2015-06-23
    Sponsor Name:Amgen Inc
    Full Title: Double-blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for Low Density Lipoprotein-Choleste...
    Medical condition: Heterozygous familial hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) IT (Completed) Outside EU/EEA GR (Completed) NL (Completed) GB (Completed) AT (Completed) HU (Completed) SI (Completed) PT (Completed) PL (Completed) NO (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-001273-81 Sponsor Protocol Number: EFC15858 Start Date*: 2019-12-17
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic Non-Squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors
    Medical condition: Non-small cell lung cancer metastatic
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) HU (Prematurely Ended) DE (Completed) PL (Completed) PT (Completed) BE (Completed) ES (Prematurely Ended) GR (Completed) BG (Ongoing) FR (Ongoing) IT (Ongoing) RO (Ongoing) LT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004344-78 Sponsor Protocol Number: EMD121974-011 Start Date*: 2008-08-28
    Sponsor Name:Merck KGaA
    Full Title: Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter, open-label, controlled Phase III study, testing cilengitide in combination wi...
    Medical condition: Newly diagnosed, histologically proven GBM with proven methylated MGMT gene promoter status
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) AT (Completed) DE (Completed) CZ (Completed) FR (Completed) ES (Prematurely Ended) IT (Prematurely Ended) SK (Completed) HU (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-005630-21 Sponsor Protocol Number: RG_06-180 Start Date*: 2009-04-09
    Sponsor Name:University of Birmingham [...]
    1. University of Birmingham
    2. Birmingham Heartlands Hospital
    Full Title: The effect of Pregabalin on Pain progressing in Painful Diabetic Neuropathy
    Medical condition: Diabtes and its complications, painful neuropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:44:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA